Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378975 | 0.85 | ALDH1A1 (0.63) | ALDH1A1KMT2ARAB9AMAPTSMN1; SMN2 | |
| SCHEMBL3378900 | 0.78 | ALDH1A1 (0.55) | ALDH1A1KMT2ARAB9AMAPTSMN1; SMN2 | |
| SCHEMBL3376534 | 0.76 | SMN1; SMN2 (0.60) | ALDH1A1KMT2ARAB9AMAPTSMN1; SMN2 | |
| SCHEMBL3375789 | 0.75 | POLB (0.38) | ALDH1A1RAB9AMAPTSMN1; SMN2PTGS2 | |
| SCHEMBL3379527 | 0.72 | ALDH1A1 (0.41) | ALDH1A1RAB9AMAPTPTGS2LMNA | |
| SCHEMBL3374842 | 0.71 | SMN1; SMN2 (0.59) | ALDH1A1RAB9AMAPTSMN1; SMN2LMNA | |
| SCHEMBL3376989 | 0.71 | SMN1; SMN2 (0.54) | ALDH1A1KMT2ARAB9AMAPTSMN1; SMN2 | |
| SCHEMBL24279552 | 0.70 | MAPT (0.50) | ALDH1A1RAB9AMAPTSMN1; SMN2LMNA | |
| SCHEMBL8302189 | 0.70 | SMN1; SMN2 (0.46) | ALDH1A1KMT2ARAB9AMAPTSMN1; SMN2 | |
| SCHEMBL3378379 | 0.70 | RAB9A (0.47) | ALDH1A1KMT2ARAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | claimed |
| WO-2010056527-A2 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNH2 | ALDH1A1 930/4885KMT2A 3186/4885RAB9A 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.